Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_131_библиотеки_им_акад_М_И_Перельмана
.pdf
111
70. Allen, A.M. Variation in Toll-like receptor 4 and susceptibility to group a
meningococcal meningitis in Gambian children / A.M. Allen [et al.] // Pediatric
Infectious Disease Journal. – 2003. – V. 22(11). – Ɋ. 1018–1019.
71. Almog, Y. Statins, inÀammation, and sepsis: hypothesis / Y. Almog [et al.] //
Chest. – 2003. – V. 124. – Ɋ. 740–743.
72. Alves-Filho, J.C. Regulation of chemokine receptor by Toll-like receptor 2 is
critical to neutrophil migration and resistance to polymicrobial sepsis / J.C.
Alves-Filho [et al.] // Proc Natl Acad Sci USA. – 2009. – V. 106(10). –
Ɋ. 4018–4023.
73. Angus, D.C. Epidemiology of severe sepsis in the United States: analysis of
incidence, outcome, and associated costs of care / D.C. Angus [et al.] // Crit
Care Med. – 2001. – V. 29. – P. 1303–1310.
74. Arbour, N.C. TLR4 mutations are associated with endotoxin
hyporesponsiveness in humans / N.C. Arbour [et al.] // Nature Genetics. –
2000. – V. 25(2). – Ɋ. 187–191.
75. Astiz,
M.E.
The
isolation
and
properties
of lipopolysaccharide
of
gram-positive
bacteria
/
M.E. Astiz
[et al.]
//
Crit.
Care
Med.
–
1995.
–
V. 23.
–
P. 9–17.
76. Aydogdu, M. Predictive factors for septic shock in patients with ventilator
associated pneumonia / M. Aydogdu [et al.] // South Med J. – 2008. – V. 101. –
P. 1222–1228.
77. Bailat,
S.
Similarities
and
disparities
between
core-specific
and
O-side
chain
specific
antilipopolysaccharide
monoclonal
antibodies
in
models
of endotoxemia
and
bacteremia
in
mice
/
S. Bailat
[et al.]
//
Infect.
Immun.
–
1997.
–
V. 65.
–
P. 811.
78. Benjamim, C.F. Reversal of long-term sepsis-induced immunosuppression by
dendritic cells / C.F. Benjamim [et al.] // Blood. – 2005. – V. 105(9). –
Ɋ. 3588–3595.
79. Bennet-Guerrero,
E.L.
Preparation
and
preclinical
evaluation
of
a
novel
liposomal
complete-core
lipopolysaccharide
vaccine
/
E.L. Bennet-
Guerrero
[et al.]
//
Infect.
Immun.
–
2000.
–
V. 68. – P. 6202–6208.
80. Bernard, G.R. Efficasy and safety of recombinant human activated protein C
for severe sepsis / G.R. Bernard [et al.] // N Eng J Med. – 2001. – V. 344. –
P. 699–709.
81. Beutler,
B.A.
TLRs
and
innate
immunity
/
B.A. Beutler
[et al.]
//
Blood.
–
2009.
–
V. 1 13 .
–
P. 1399–1407.
82. Bjorkbacka,
H.
The
induction
of macrophage
gene
expression
by
LPS
predominantly
utilizes
MyD88-independent
signaling
cascades /
H. Bjorkbacka
[et al.] //
Physiol.
Genomics.
–
2004.
–
V. 19.
–
P. 319–330.
83. Blanco-Colio, L.M. AntiinÀammatory and immunomodulatory effects of
statins / L.M. Blanco-Colio [et al.] // Kidney Int. – 2003. – V. 63. – Ɋ. 12–23.
84. Bone, R.C. Sepsis: a new hypothesis for pathogenesis of the disease process /
R.C. Bone [et al.] // Chest. – 1997. – V. 112(1). – Ɋ. 235–243.
https://t.me/med1917
112
85. Bonnet, J. CAP Investigators. Comparative effects of 10-mg versus 80-mg
Atorvastatin on high-sensitivity C-reactive protein in patients with stable
coronary artery disease: results of the CAP (Comparative Atorvastatin
Pleiotropic effects) study / J. Bonnet // Clin Ther. – 2008. – V. 30. – Ɋ. 2298–
2313.
86. Boomer, J.S. Immunosuppression in patients who die of sepsis and multiple
organ failure / J.S. Boomer // JAMA. – 2011. – V. 306(23). – Ɋ. 2594–2605.
87. Bosshart,
H.
Tar geti ng
bacterial
endotoxin:
two
sides
of
a
coin / H. Bosshart
// Ann.
NY
Acad.
Sci.
–
2007.
–
V. 1096.
–
P. 1-17.
88. Brent, A.J. Incidence of clinically significant bacteraemia in children who
present to hospital in Kenya: community-based observational study / A.J. Brent
[et al.] // Lancet. – 2006. – V. 367. – V. 9509. – P. 482–488.
89. Brookes, A.J. The essence of SNPs / A.J. Brookes [et al.] // Gene. – 1999. –
V. 234(2). – Ɋ. 177–186.
90. Brun–Buisson, C. Incidence, risk factors, and outcome of severe sepsis and
septic shock in adults. A multicenter, prospective study in intensive care units.
French ICU Group for Severe Sepsis / C. Brun–Buisson [et al.] // JAMA. –
1995. – V. 274. – P. 968–74.
91. Bryant,
C.E.
The
molecular
basis
of
the
host response
to
lipopolysaccharide
/
C.E. Bryant
[et al.]
//
Nat.
Rev.
Microbiol.
–
2010.
–
V. 8 .
–
P. 8-14.
92. Buda, S. Clinical experience with polyclonal IgM-enriched immunoglobulins
in a group of patients affected by sepsis after cardiac surgery / S. Buda [et al.] //
J. Cardiothorac. Vasc. Anesth. – 2005. – V. 19(4). – P. 440–445.
93. Buerke, U. Apoptosis contributes to septic cardiomyopathy and is improved by
simvastatin therapy / U. Buerke // Shock 2008. – V. 29. – Ɋ. 497–503.
94. Bunnell,
E.
A
lipid
A
analog,
E5531,
blocks
the
endotoxin
response
in
human
Vunteers
with
experimental
endotoxemia
/
E. Bunnell
//
Crit.
Care
Med.
–
2000.
–
V. 28. – P. 2713–2720.
95. Carson, W.F. Epigenetic regulation of immune cell functions during post-
septic immunosuppression / W.F. Carson // Epigenetics. – 2011. – V. 6(3). –
Ɋ. 273–283.
96. Cavassani, K.A. The post sepsis-induced expansion and enhanced function of
regulatory T cells create an environment to potentiate tumor growth / K.A.
Cavassani // Blood. – 2010. – V. 115(22). – Ɋ. 4403–4411.
97. Cazalis, M.A. Decreased HLA-DR antigen-associated invariant chain (CD74)
mRNA expression predicts mortality after septic shock / M.A. Cazalis // Crit
Care. – 2013. – V. 17(6).
98. Chang, K. Targeting the programmed cell death 1: programmed cell death
ligand 1 pathway reverses T-cell exhaustion in patients with sepsis / K. Chang
[et al.] // Crit Care. – 2014. – V. 18. – P. 3.
99. Cheadle, W.G. Comparison of trauma assessment scores and their use in
prediction of infection and death / W.G. Cheadle // Ann Surg. – 1989. –
V. 209(5). – Ɋ. 541–545.
https://t.me/med1917
113
100. Christ-Crain, M. Mid-regional pro-adrenomedullin as a prognostic marker in
sepsis: an observational study / M. Christ-Crain [et al.] // Crit Care. – 2005. –
V. 9. – P. 816–824.
101. Chu, D.J. Effects of tuftsin on postsplenectomy sepsis / D.J. Chu [et al.] //
Surgery. – 1985. – V. 97(6). – P. 701–705.
102. Cooper, M. Splenectomy: indication, hazards and alternatives / M. Cooper [et
al.] // Brit. J. Surg. – 1984. – V. 71. – P. 137–180.
103. Crawford, B. Permanente Northern California sepsis mortality reduction
initiative / B. Crawford [et al.] // Critical Care. – 2012. – V. 16 (Suppl 3). –
P. 12.
104. Cuenca, A.G. Development of a genomic metric that can be rapidly used to
predict clinical outcome in severely injured trauma patients / A.G. Cuenca //
Crit Care Med. – 2013. – V. 41(5). – Ɋ. 1175–1185.
105. Cuzon, Gaële. Worldwide Diversity of Klebsiella pneumoniae That Produces
ȕ-Lactamase blaKPC-2 Gene / Gaële Cuzon [et al.] // Emerging Infectious
Diseases. – 2010. – V. 16. – P. 1349–1356.
106. de Jong, E. Efficacy and safety of procalcitonin guidance in reducing the
duration of antibiotic treatment in critically ill patients: a randomized,
controlled, open-label trial / E. de Jong [et al.] // Lancet Infect Dis. – 2016. –
V. 16(7). – P. 819–827.
107. Deitch, E.A. Prevention of multiple organ failure / E.A. Deitch [et al.] //
Surg.Clin. N. Amer. – 1999. – V. 79(6). – P. 1471–1488.
108. Delano, M.J. Sepsis-induced immune dysfunction: Can immune therapies
reduce mortality? / M.J. Delano [et al.] // J. Clin. Investig. – 2016. – V. 126. –
P. 23–31.
109. Dellinger, R.P. Surviving sepsis campaign: international guidelines for
management of severe sepsis and septic shock: 2008 / R.P. Dellinger [et al.] //
Crit Care Med. – 2008. – V. 36. – P. 296–327.
110. Delsing, C.E. Interferon-gamma as adjunctive immunotherapy for invasive
fungal infections: a case series / C.E. Delsing [et al.] // BMC Infect Dis. –
2014. – V. 14. – P. 166.
111. Demaret, J. STAT5 phosphorylation in T cell subsets from septic patients in
response to recombinant human interleukin-7: a pilot study / J. Demaret //
J Leukoc Biol. – 2015. – V. 97(4). – Ɋ. 791–796.
112. Derek, C. A Framework for the Development and Interpretation of Different
Sepsis Definitions and Clinical Criteria / C. Derek [et al.] // Critical. Care
Medicine. – 2016. – V. 44(3). – Ɋ. 113–121.
113. Deutschman, C.S. The Third International Consensus Definitions for Sepsis
and Septic Shock (Sepsis-3) / C.S. Deutschman [et al.] // JAMA. – 2016. –
V. 315(8). – Ɋ. 801–810.
114. Dobesh, P.P. Reduction in mortality associated with statin therapy in patients
with severe sepsis / P.P. Dobesh // Pharmacotherapy. – 2009. – V. 29. –
Ɋ. 621–630.
https://t.me/med1917
114
115. Docke, W.D. Monocyte deactivation in septic patients: restoration by IFN-
gamma treatment / W.D. Docke // Nat Med. – 1997. – V. 3(6). – Ɋ. 678–681.
116. Dombrovskiy, V.Y. Rapid increase in hospitalization and mortality rates for
serve sepsis in the United States: a trend analysis from 1993–2003 / V.Y.
Dombrovskiy [et al.] // Crit Care Med. – 2007. – V. 35. – Ɋ. 1244–50.
117. Domínguez-Andrés, J. The itaconate pathway is a central regulatory node
linking innate immune tolerance and trained immunity / J. Domínguez-Andrés
[et al.] // Cell Metabolism. – 2018. – V. 29(1). – Ɋ. 1550–4131.
118. Donta,
S.T.
Immunoprophylaxis
against
Klebsiella
and
P.aeruginosa
infections
/
S.T. Donta
//
J . Infect.
Dis.
–
1996.
–
V. 174.
–
P. 537–543.
119. Dou, X.M. Correlations between ACE single nucleotide polymorphisms and
prognosis of patients with septic shock / X.M. Dou // Bioscience Reports. –
2017. – V. 37(2). – BSR20170145.
120. Douzinas, E.E. Prevention of infection in multiple trauma patients by high-
dose intravenous immunoglobulins / E.E. Douzinas [et al.] // Crit. Care Med. –
2000. – V. 28(1). – Ɋ. 8–15.
121. Dries, D.J. Effect of interferon gamma on infection-related death in patients
with severe injuries. A randomized, double-blind, placebo-controlled trial / D.J.
Dries // Arch Surg. – 1994. – V. 129(10). – Ɋ. 1031–1041.
122. Endo, S. Usefulness of presepsin in the diagnosis of sepsis in a multicenter
prospective study / S. Endo // J Infect Chemother, – 2012. – V. 18(6). – Ɋ. 891–
897.
123. Enguix-Armada, A. Usefulness of several biomarkers in the management of
septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional
pro-adrenomedullin / A. Enguix-Armada // Clin Chem Lab Med. – 2016. –
V. 54(1). – P. 163–171.
124. Fashing, M.D. Reimmunization and splenic autotransplantation a longterm of
immunologic response and survival following pneumococcal challenge / M.D.
Fashing [et al.] // J. Surg. Res. – 1980. – V. 449. – P. 591.
125. Flohe, S. Effect of granulocyte-macrophage colony-stimulating factor on the
immune response of circulating monocytes after severe trauma / S. Flohe [et
al.] // Crit Care Med. – 2003. – V. 31. – P. 2462–2469.
126. Francois, B. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7
randomized clinical trial / B. Francois [et al.] // JCI Insight. – 2018. – V. 3. –
P. 98960.
127. Fraunberger, P. Simvastatin reduces endotoxininduced nuclear factor kappaB
activation and mortality in guinea pigs despite lowering circulating low-density
lipoprotein cholesterol / P. Fraunberger // Shock. – 2009. – V. 32. – Ɋ. 159–63.
128. Friedman, G. Has the mortality of septic shock changed with time /
G. Friedman [et al.] // Crit Care Med. – 1998. – V. 26. – P. 2078–2086.
129. Gabrilovich, D.I. Coordinated regulation of myeloid cells by tumours / D.I.
Gabrilovich // Nat Rev Immunol. – 2012. – V. 12(4). – Ɋ. 253–268.
https://t.me/med1917
115
130. Gao, J-W. Association between IL-6-174G/C polymorphism and the risk of
sepsis and mortality: a systematic review and meta-analysis / J-W. Gao // PLoS
One [Internet]. – 2015. – 10(3).
131. Gao, X. Therapeutic targeting of apoptosis inhibitor of macrophage
(AIM)/CD5L in sepsis / X. Gao [et al.] // Am J Respir Cell Mol Biol [online
ahead of print]. – 16 Oct 2018.
132. Gay,
N.J.
Toll-like
receptors
as
molecular
switches / N.J. Gay
//
Nature
Rev.
Immunol.
–
2006.
–
V. 6 .
–
P. 693-698.
133. Giamarellos-Bourboulis, E.J. The role of genetics and antibodies in sepsis /
E.J. Giamarellos-Bourboulis // Annals of Translational Medicine. – 2016. –
V. 4(17). – 328.
134. Goto, M. Overall burden of bloodstream infection and nosocomial
bloodstream infection in North America and Europe / M. Goto, M.N. Al-Hasan
// Clinical microbiology and infection: the official publication of the European
Society of Clinical Microbiology and Infectious Diseases. – 2013. – V. 19(6). –
P. 501–509.
135. Grailer, J.J. Persistent neutrophil dysfunction and suppression of acute lung
injury in mice following cecal ligation and puncture sepsis / J.J. Grailer //
J Innate Immun. – 2014. – V. 6(5). – Ɋ. 695–705.
136. Grimaldi, D. Specific MAIT cell behaviour among innate-like T lymphocytes
in critically ill patients with severe infections / D. Grimaldi // Intensive Care
Med. – 2014. – V. 40(2). – Ɋ. 192–201.
137. Grube, M. Donor Nucleotide-Binding Oligomerization-Containing Protein 2
(NOD2) Single Nucleotide Polymorphism 13 Is Associated with Septic Shock
after Allogeneic Stem Cell Transplantation / M. Grube // Biology of Blood and
Marrow Transplantation. – 2015. – V. 21(8). – Ɋ. 1399–1404.
138. Gutcher, I. APC-derived cytokines and T cell polarization in autoimmune
inflammation / I. Gutcher // J Clin Invest. – 2007. – V. 117(5). – Ɋ. 1119–1127.
139. Guthy, E. Traitement des blessures de la rate par coagulation aux intra-rouges
/ E. Guthy // J. Chir. (Paris). – 1981. – V. 118(6/7). – P. 429–431.
140. Hackam, D.G. Statins and sepsis in patients with cardiovascular disease: a
populationbased cohort analysis / D.G. Hackam // Lancet. – 2006. – V. 367. –
Ɋ. 413–418.
141. Hailman, E. Lipopolysaccharide (LPS)-binding protein accelerates the
binding of LPS to CD14 / E. Hailman // J Exp Med. – 1994. – V. 179(1). –
Ɋ. 269–277.
142. Hall, M.W. Immunoparalysis and nosocomial infection in children with
multiple organ dysfunction syndrome / M.W. Hall [et al.] // Inten Care Med. –
2011. – V. 37. – P. 525–532.
143. Hamburg, M.A. The path to personalized medicine / M.A. Hamburg // N Engl
J Med. – 2010. – V. 363(4). – Ɋ. 301–304.
https://t.me/med1917
116
144. He, W.T. Gasdermin D is an executor of pyroptosis and required for
interleukin-1ȕ secretion / W.T. He // Cell Res. – 2015. – V. 25. – Ɋ. 1285–
1298.
145. Hinson, J.P. Adrenomedullin, a multifunctional regulatory peptide / J.P.
Hinson // Endocr Rev. – 2000. – V. 21. – Ɋ. 138–67.
146. Horn, M.P. Simvastatin inhibits Staphylococcus aureus host cell invasion
through modulation of isoprenoid intermediates / M.P. Horn // J Pharmacol Exp
Ther. – 2008. – V. 326. – Ɋ. 135–43.
147. Hotchkiss, R.S. Immunosuppression in sepsis: a novel understanding of the
disorder and a new therapeutic approach / R.S. Hotchkiss [et al.]. // Lancet
Infect Dis. – 2013. – V. 13. – P. 260–268.
148. Howell, M.D. Management of Sepsis and Septic Shock / M.D. Howell //
JAMA. – 2017. – V. 317(8). – Ɋ. 847–848.
149. Hu, J.J. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin
D pore formation / J.J. Hu [et al.]. // Nat Immunol. – 2020. – V. 21. – Ɋ. 736–
745.
150. Hutchins, N.A. The new normal: immunomodulatory agents against sepsis
immune suppression / N.A. Hutchins [et al.]. // Trends Mol Med. – 2014. –
V. 20(4). – Ɋ. 224–233.
151. Inoue, S. IL-15 prevents apoptosis, reverses innate and adaptive immune
dysfunction, and improves survival in sepsis / S. Inoue [et al.]. // J Immunol. –
2010. – V. 184(3). – Ɋ. 1401–1409.
152. Ishii, M. Epigenetic regulation of the alternatively activated macrophage
phenotype / M. Ishii [et al.]. // Blood. – 2009. – V. 114(15). – Ɋ. 3244–3254.
153. Iwashyna, T.J. Spurious inferences about long-term outcomes: the case of
severe sepsis and geriatric conditions / T.J. Iwashyna [et al.] // American
journal of respiratory and critical care medicine. – 2012. – V. 185, V. 8. –
P. 835–841.
154. Jean-Baptiste,
E.
Cellular
mechanisms
in
sepsis
/
E. Jean-Baptiste
//
J.
Intens.
Care
Med.
–
2007,
V. 22, P. 63–72.
155. Jeeva, M. Sepsis in the newborn / M. Jeeva [et al.]. // The Indian J. of
Pediatrics. – 2008. – V. 75. – P. 261–266.
156. Jimenez-Sousa, M.A. Association of CD14 rs2569190 polymorphism with
mortality in shock septic patients who underwent major cardiac or abdominal
surgery: a retrospective study / M.A. Jimenez-Sousa [et al.]. // Scientific
Reports. – 2018. – V. 8(1). – Ɋ. 2698.
157. Joshua, S.D. Sepsis in the tropical Top End of Australia’s Northern Territory:
disease burden and impact on Indigenous Australians / S.D. Joshua [et al.] //
MJA. – 2011. – V. 194(10). – P. 519–524.
158. Karabinis, A. Colistin for Klebsiella pneumonia – Associated Sepsis /
A. Karabinis [et al.]. // Clin. Infect. Dis. – V. 38 (1). – P. 7–9.
https://t.me/med1917
117
159. Kawata,
T.
E5531, a synthetic non-toxic lipid A derivative blocks the
immunological activities of lipopolysaccharide / T. Kawata
[et al.]. // Br.
J.
Pharmacol. –
1999.
–
V. 127.
–
P. 853–862.
160. Kayagaki, N. Caspase-11 cleaves gasdermin D for non-canonical
infammasome signalling / N. Kayagaki [et al.]. // Nature. – 2015. – V. 526. –
Ɋ. 666–671.
161. Kelly-Scumpia, K.M. B cells enhance early innate immune responses during
bacterial sepsis / K.M. Kelly-Scumpia // J Exp Med. – 2011. – V. 208(8). –
Ɋ. 1673–1682.
162. Kim,
H.M.
Crystal
structure
of
the
TLR4-MD-2
complex
with
bound
endotoxin
antagonist
Eritoran
/
H.M. Kim
[et al.].
//
Cell.
–
2007.
–
V.130.
–
P. 906–917.
163. Kinter, A.L. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-
21 induce the expression of programmed death-1 and its ligands / A.L. Kinter //
J Immunol. – 2008. – V. 181(10). – Ɋ. 6738–6746.
164. Kox, W.J. Interferon gamma-1b in the treatment of compensatory anti-
inflammatory response syndrome. A new approach: proof of principle / W.J.
Kox [et al.]. // Archi Inter Med. – 1997. – V. 157. – P. 389–393.
165. Krisztina, A. Tribble Invasive Klebsiella pneumoniae Syndrome in North
America / A. Krisztina // Clin. Infect. Dis. – 2007. – V. 45 (3). – P. 25–28.
166. Kulabukhov, V. Use of an endotoxin adsorber in the treatment of severe
abdominal sepsis / V.Kulabukhov // Acta Anaesthesiol. Scand. – 2008. – V. 52.
– Ɋ.1024–1025.
167. Landelle, C. Low monocyte human leukocyte antigen-DR is independently
associated with nosocomial infections after septic shock / C. Landelle [et al.]. //
Intensive Care Med. – 2010. – V. 36(11). – Ɋ. 1859–1866.
168. Lark, R.L. Four year prospective evaluation of nosocomial bacteremia:
epidemiology, microbiology, and patient outcome / R.L. Lark [et al.]. //
Diagnostic microbiology and infectious disease. – 2000. – V. 38(3). – P. 131–
140.
169. Leentjens, J. Reversal of immunoparalysis in humans in vivo: a double-blind,
placebo-controlled, randomized pilot study / J. Leentjens [et al.]. // Am J Resp
Crit Care Med. – 2012. – V. 186. – P. 838–845.
170. Leibovici, L. Long-term consequences of severe infections / L. Leibovici //
Clinical microbiology and infection: the offi cial publication of the European
Society of Clinical Microbiology and Infectious Diseases. – 2013. – V. 19(6). –
P. 510–512.
171. Leon,
C.G.
Discovery
and
development
of Toll-like
receptor
4
(TLR4)
antagonists:
a
new
paradigm
for
treating
sepsis
and other
disease
/
C.G.
Leon
[et al.].
//
Pharm.
Res.
–
2008.
–
V. 25(8).
–
P. 1751–1761.
172. Lerman, Y.V. Sepsis lethality via exacerbated tissue infiltration and TLR-
induced cytokine production by neutrophils is integrin alpha3beta1-dependent /
Y.V. Lerman [et al.]. // Blood. – 2014. – V. 124(24). – Ɋ. 3515–3523.
https://t.me/med1917
118
173. Levy, Y. Effects of recombinant human interleukin 7 on T-cell recovery and
thymic output in HIV-infected patients receiving antiretroviral therapy: results
of a phase I/IIa randomized, placebo-controlled, multicenter study / Y. Levy [et
al.]. // Clin Infect Dis. – 2012. – V. 55(2). – Ɋ. 291–300.
174. Lewis, D.H. The immunopathology of sepsis: pathogen recognition, systemic
inflammation, the compensatory antiinflammatory response, and regulatory
T cells / D.H. Lewis [et al.]. // Journal of Veterinary Internal Medicine. – 2012.
– V. 26. Ɋ. 457–482.
175. Lieschke, G.J. Mice lacking granulocyte colony-stimulating factor have
chronic neutropenia, granulocyte and macrophage progenitor cell deficiency,
and impaired neutrophil mobilization / G.J. Lieschke [et al.]. // Blood. – 1994.
– V. 84(6). – Ɋ. 1737–1746.
176. Lillie, P.J. Long-term mortality following bloodstream infection / P.J. Lillie
[et al.] // Clinical microbiology and infection: the offi cial publication of the
European Society of Clinical Microbiology and Infectious Diseases. – 2012.
177. Limaye, A.P. Cytomegalovirus reactivation in critically ill immunocompetent
patients / A.P. Limaye // JAMA. – 2008. – V. 300(4). – Ɋ. 413–422.
178. Link, D.C. Neutrophil homeostasis: a new role for stromal cell-derived
factor-1 / D.C. Link // Immunol Res. – 2005. – V. 32(1-3). – Ɋ. 169–178.
179. Linscheid, P. Autocrine / paracrine role of inflammation-mediated calcitonin
generelated peptide and adrenomedullin expression in human adipose tissue /
P. Linscheid // Endocrinology. – 2005. – V. 146. – Ɋ. 2699–2708.
180. Liston A. Homeostatic control of regulatory T cell diversity / // Nat Rev
Immunol. – 2014. – V. 14(3). – Ɋ. 154–165.
181. Liu,
L.
Structural
basis
of
toll-like
receptor
3
signaling
with
double-
stranded
RNA / L. Liu
[et al.]. / / Science.
–
2008.
–
V. 320.
–
P. 379–381.
182. Liu, Z-L. The CD40 rs1883832 Polymorphism Affects Sepsis Susceptibility
and sCD40L Levels / Z-L. Liu // BioMed Research International [Internet]. –
2018. – 7497314.
183. Lv, S. Anti-TNF-alpha therapy for patients with sepsis: a systematic meta-
analysis / S. Lv [et al.]. // Inter J Clin Pract. – 2014. – V. 68. – P. 520–528.
184. Lynn,
M.
Blocking
of
responses
to
endotoxin
by
E5564
in
healthy
Vunteers
with
experimental
endotoxemia
/
M. Lynn
//
J. Infect.
Dis.
–
2003.
–
V. 187.
–
P. 631–639.
185. Mackall, C.L. Harnessing the biology of IL-7 for therapeutic application /
C.L. Mackall [et al.]. // Nat Rev Immunol. – 2011. – V. 11(5). – Ɋ. 330–342.
186. Marchaim, D. et al. Epidemiology of bacteremia episodes in a single center:
increase in Gram-negative isolates, antibiotics resistance, and patient age /
D. Marchaim [et al.] // European journal of clinical microbiology & infectious
diseases: official publication of the European Society of Clinical Microbiology.
– 2008. – V. 27(11). – P. 1045–1051.
https://t.me/med1917
119
187. Marenoviü, T. High doses of immunoglobulins decrease mortality rate of
surgical patients with severe intraabdominal infections and sepsis /
T. Marenoviü [et al.] // Vojnosanit Pregl. – 1998. – V. 55 (2 Suppl). – P. 71–74.
188. Martin, G.S. The effect of age on the development and outcome of adult
sepsis / G.S. Martin // Crit Care Med. – 2006. – V. 34(1). – Ɋ. 15–21.
189. Martinon, F. The inflammasome: a molecular platform triggering activation
of inflammatory caspases and processing of proIL-beta / F. Martinon // Mol
Cell. – 2002 Aug. – V. 10(2). – Ɋ. 417-26.
190. Matthew, J.D. Sepsis-induced immune dysfunction: can immune therapies
reduce mortality? / J.D. Matthew [et al.]. // J Clin Invest. – 2016 Jan 4. –
V. 126(1). – Ɋ. 23–31.
191. Mayer, C. Rosuvastatin reduces interleukin-6-induced expression of C-re-
active protein in human hepatocytes in a STAT3- and C/EBP-dependent
fashion / C. Mayer // Int J Clin Pharmacol Ther. – 2007. – V. 45. – Ɋ. 319–327.
192. McGown, C.C. Bene¿cial effects of statins on the microcirculation during
sepsis: the role of nitric oxide / C.C. McGown // Br J Anaesth. – 2007. – V. 98.
– Ɋ. 163–175.
193. Meisel, C. Granulocyte-macrophage colony-stimulating factor to reverse
sepsisassociated immunosuppression: a double-blind, randomized,
placebocontrolled multicenter trial / C. Meisel [et al.]. // Am J Respir Crit Care
Med. – 2009. – V. 180. – P. 640–648.
194. Merx, M.W. HMG-CoA reductase inhibitor simvastatin profoundly improves
survival in a murine model of sepsis / M.W. Merx [et al.]. // Circulation. –
2004. – V. 109. – Ɋ. 2560–2565.
195. Michalek, J. Bactericidal permeability increasing protein gene variants in
children with sepsis / J. Michalek [et al.]. // Intensive Care Medicine. – 2007. –
V. 33(12). – Ɋ. 2158–2164.
196. Miniño, A.M. Deaths: final data for 2008 / A.M. Miniño [et al.] // National
vital statistics reports: from the Centers for Disease Control and Prevention,
National Center for Health Statistics, National Vital Statistics System. – 2011. –
V. 59(10). – P. 1–126.
197. Monneret, G. ICU-acquired immunosuppression and the risk for secondary
fungal infections / G. Monneret [et al.]. // Med. Mycol. – 2011. – V. 49, Suppl.
1. – P. 17–23.
198. Monserrat, J. Early alterations of B cells in patients with septic shock /
J. Monserrat // Crit Care. – 2013. – 17(3).
199. Montecucco, F. Statins inhibit C-reactive protein-induced chemokine
secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes
/ F. Montecucco // Rheumatol Oxf. – 2009. – V. 48. – Ɋ. 233–242.
200. Moore, F.A. E Vving concepts in the pathogenesis of postinjury multiple
organ failure / F.A. Moore // Surg Clin North Am. – 1995. – V. 75(2). –
Ɋ. 257–277.
https://t.me/med1917
120
201. Moore, L.J. Validation of a screening tool for the early identification of sepsis
/ L.J. Moore [et al.]. // J Trauma. – 2009. – V. 66. – Ɋ. 1539–47.
202. Morris, A.C. C5a-mediated neutrophil dysfunction is RhoA-dependent and
predicts infection in critically ill patients / A.C. Morris // Blood. – 2011. –
V. 117(19). – Ɋ. 5178–5188.
203. Mortensen, E.M. Impact of previous statin and angiotensin II receptor
blocker use on mortality in patients hospitalized with sepsis / E.M. Mortensen
// Pharmacotherapy. – 2007. – V. 27. – Ɋ. 1619–1626.
204. Munoz, C. Dysregulation of in vitro cytokine production by monocytes
during sepsis / C. Munoz [et al.]. // J Clin Invest. – 1991. – V. 88(5). –
Ɋ. 1747–1754.
205. Munoz-Price, L.S. Clinical epidemiology of the global expansion of
Klebsiella pneumoniae carbapenemases / L.S. Munoz-Price [et al.]. // Lancet
Infect Dis. – 2013. – Sep. – 13 (9). – 785–96.
206. Murdoch, D.R. Microbiological patterns in sepsis: what happened in the last
20 years? / D.R. Murdoch // International journal of antimicrobial agents. –
2009. – V. 34, suppl 4, – P. 5–8.
207. Nachtigall, I. Polymorphisms of the toll-like receptor 2 and 4 genes are
associated with faster progression and a more severe course of sepsis in
critically ill patients / I. Nachtigall [et al.]. // Journal of International Medical
Research. – 2014. – V. 42(1). – Ɋ. 93–110.
208. Nacionales, D.C. Aged mice are unable to mount an effective myeloid
response to sepsis / D.C. Nacionales [et al.]. // J Immunol. – 2014. – V. 192(2).
– Ɋ. 612–622.
209. Nalos, M. Immune effects of interferon gamma in persistent staphylococcal
sepsis / M. Nalos [et al.]. // Am J Resp Crit Care Med. – 2012. – V. 185. –
P. 110–112.
210. Nathan, C. Neutrophils and immunity: challenges and opportunities /
C. Nathan // Nat Rev Immunol. – 2006. – V. 6(3). – Ɋ. 173–182.
211. Needham, D.M. Improving long-term outcomes after discharge from
intensive care unit: report from a stakeholders conference / D.M. Needham [et
al.]. // Crit Care Med. – 2012. – V. 40(2). – Ɋ. 502–509.
212. Nguyen, H.B. Implementation of a bundle of quality indicators for the early
management of severe sepsis and septic shock is associated with decreased
mortality / H.B. Nguyen [et al.]. // Crit Care Med. – 2007. – V. 35. – Ɋ. 1105–
1112.
213. Nur, B. Epidemiology of sepsis in intensive care units in Turkey: a
multicenter, point-prevalence study / B. Nur [et al.]. // Critical Care. – 2018. –
V. 22 (93). – P. 14.
214. O’Neill,
L.A.
The
family
of
five:
TIR-domain-containing
adaptors in
Toll-like
receptor
signaling
/
L.A. O’Neill
[et al.].
//
Nature
Rev.
Immunol.
–
2007,
V. 7 ,
P. 353-364.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана